Reprint notice: This is a short digest based on public FDA information. Copyright remains with the original publisher.
On July 22, 2026, the FDA named Dexcom as the first participant in its TEMPO digital health devices pilot. The program will collect real-world data to evaluate patient outcomes and technology-supported chronic care.
Source：U.S. Food and Drug Administration · View original ↗